Astodrimer is under clinical development by Starpharma and currently in Phase I for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase I drugs for Coronavirus Disease 2019 (COVID-19) have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Astodrimer’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Astodrimer overview
Astodrimer (VivaGel BV, Fleurstat BV SPL7013, Betafem BV) acts as an microbicide. It is formulated as gel for vagina route of application. It is indicated for treatment of bacterial vaginosis (BV) including symptoms and also for the prevention of recurrent bacterial vaginosis.
Astodrimer is under development for the treatment of Coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS), influenza virus A and B infection, HIV, genital herpes infections and human papillomavirus infections. It is administered as gel for vagina and ophthalmic eye drops for viral conjunctivitis. The drug candidate is based on dendrimer nanotechnology. It was also under viral conjunctivitis, bacterial vaginosis and Zika virus.
Starpharma overview
Starpharma is a biotechnology company. It is advancing dendrimer technology to develop innovative therapeutics, particularly targeting serious conditions like cancer. The company’s proprietary dendrimer-based platform, DEP (Dendrimer Enhanced Product), enhances drug delivery by improving solubility, stability, bioavailability, and reducing toxicity. The technology enables targeted drug delivery to specific sites, such as tumors, optimizing therapeutic effects while minimizing side effects. The company’s product portfolio includes antimicrobial products based on its dendrimer SPL7013, such as Viraleze nasal spray, VivaGel BV, and VivaGel condom, which provide antiviral protection. Its clinical-stage oncology pipeline includes DEP SN38, DEP cabazitaxel, and DEP docetaxel. Starpharma is headquartered in Abbotsford, Victoria, Australia.
For a complete picture of Astodrimer’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
